{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:30:43Z","timestamp":1790742643821,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007650","name":"Fundaci\u00f3n Canaria de Investigaci\u00f3n y Salud","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007650","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Research"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.psychres.2017.01.043","type":"journal-article","created":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T05:31:40Z","timestamp":1484803900000},"page":"200-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Low levels of serum total antioxidant capacity and presence at admission and absence at discharge of a day\/night change as a marker of acute paranoid schizophrenia relapse"],"prefix":"10.1016","volume":"249","author":[{"given":"Armando L.","family":"Morera-Fumero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda","family":"D\u00edaz-Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Abreu-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lourdes","family":"Fernandez-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria del Rosario","family":"Cejas-Mendez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.psychres.2017.01.043_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/1756-0500-5-169","article-title":"Inter-relationship of plasma markers of oxidative stress and thyroid hormones in schizophrenics","volume":"5","author":"Akiibinu","year":"2012","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.psychres.2017.01.043_bib2","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0278-5846(02)00220-8","article-title":"The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant\/antioxidant imbalance","volume":"26","author":"Akyol","year":"2002","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2017.01.043_bib3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.pnpbp.2013.04.020","article-title":"Reduced total antioxidant level and increased oxidative stress in patients with deficit schizophrenia: a preliminary study","volume":"45","author":"Albayrak","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2017.01.043_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000202823","article-title":"Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients","volume":"59","author":"Al-Chalabi","year":"2009","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.psychres.2017.01.043_bib5","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.psychres.2017.01.043_bib6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.schres.2013.03.017","article-title":"A study to evaluate the effect of celecoxib as add-on to olanzapine therapy in schizophrenia","volume":"147","author":"Baheti","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2017.01.043_bib7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1600-079X.1999.tb00597.x","article-title":"Physiological levels of melatonin contribute to the antioxidant capacity of human serum","volume":"27","author":"Benot","year":"1999","journal-title":"J. Pineal Res."},{"key":"10.1016\/j.psychres.2017.01.043_bib8","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1017\/neu.2013.44","article-title":"Are oxidative stress markers useful to distinguish schizoaffective disorder from schizophrenia and bipolar disorder?","volume":"26","author":"Bulbul","year":"2014","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.psychres.2017.01.043_bib9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0899-9007(00)00570-0","article-title":"Reactive oxygen species in human health and disease","volume":"17","author":"Castro","year":"2001","journal-title":"Nutrition"},{"key":"10.1016\/j.psychres.2017.01.043_bib10","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jpsychires.2010.03.008","article-title":"Reduced status of plasma total antioxidant capacity in schizophrenia with tardive dyskinesia","volume":"44","author":"Chen","year":"2010","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.psychres.2017.01.043_bib11","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1440-1819.2010.02132.x","article-title":"Lipid peroxidation in patients with schizophrenia","volume":"64","author":"Dietrich-Muszalska","year":"2010","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2017.01.043_bib12","doi-asserted-by":"crossref","first-page":"562429","DOI":"10.1155\/2013\/562429","article-title":"Status of systemic oxidative stress during therapeutic hypothermia in patients with post-cardiac arrest syndrome","volume":"2013","author":"Dohi","year":"2013","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.psychres.2017.01.043_bib13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clinbiochem.2003.11.015","article-title":"A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation","volume":"37","author":"Erel","year":"2004","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.psychres.2017.01.043_bib14","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00406-012-0294-y","article-title":"Neurobiology of schizophrenia: from outcome to pathophysiological insights","volume":"262","author":"Falkai","year":"2012","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2017.01.043_bib15","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.biopsych.2013.03.018","article-title":"Meta-analysis of oxidative stress in schizophrenia","volume":"74","author":"Flatow","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2017.01.043_bib16","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/S0891-5849(00)00394-4","article-title":"Total antioxidant capacity as a tool to assess redox status: critical view and experimental data","volume":"29","author":"Ghiselli","year":"2000","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.psychres.2017.01.043_bib17","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.psychres.2017.01.043_bib18","series-title":"Radicals (free radicals). Compendium of Chemical Terminology","first-page":"1234","author":"International Union of Pure and Applied Chemistry (IUPAC)","year":"1997"},{"key":"10.1016\/j.psychres.2017.01.043_bib19","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.schres.2007.01.019","article-title":"Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro","volume":"92","author":"Kato","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2017.01.043_bib20","first-page":"1064","article-title":"Reduced plasma total antioxidant status in first-episode drug-naive patients with schizophrenia. Prog. Neuropsychopharmacol","volume":"35","author":"Li","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2017.01.043_bib21","first-page":"345","article-title":"Plasma total antioxidant capacity (TAC) in obese Malaysian subjects","volume":"18","author":"Lim","year":"2012","journal-title":"Malays. J. Nutr."},{"key":"10.1016\/j.psychres.2017.01.043_bib22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.brainres.2009.05.063","article-title":"Clozapine protects PC-12 cells from death due to oxidative stress induced by hydrogen peroxide via a cell-type specific mechanism involving inhibition of extracellular signal-regulated kinase phosphorylation","volume":"1283","author":"Magliaro","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.psychres.2017.01.043_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-244X-11-26","article-title":"Reduced antioxidant defense in early onset first-episode psychosis: a case-control study","volume":"11","author":"Mico","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.psychres.2017.01.043_bib24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1042\/cs0840407","article-title":"A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status in premature neonates","volume":"84","author":"Miller","year":"1993","journal-title":"Clin. Sci."},{"key":"10.1016\/j.psychres.2017.01.043_bib25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1600-079X.2007.00467.x","article-title":"Daytime\/night-time and summer\/winter melatonin and malondialdehyde rhythms: an inverse relationship","volume":"43","author":"Morera","year":"2007","journal-title":"J. Pineal Res."},{"key":"10.1016\/j.psychres.2017.01.043_bib26","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1080\/15622970801901802","article-title":"Winter\/summer seasonal changes in malondialdehyde formation as a source of variance in oxidative stress schizophrenia research","volume":"10","author":"Morera","year":"2009","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2017.01.043_bib27","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.3390\/ijms14059037","article-title":"Role of melatonin in schizophrenia","volume":"14","author":"Morera-Fumero","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.psychres.2017.01.043_bib28","first-page":"1089","article-title":"Evaluation of total antioxidant status, total oxidant status and oxidative stress index in patients with alopecia areata","volume":"7","author":"Motor","year":"2014","journal-title":"Int. J. Clin. Exp. Med."},{"key":"10.1016\/j.psychres.2017.01.043_bib29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/hup.1102","article-title":"Association between plasma nitric oxide metabolites levels and negative symptoms of schizophrenia: a pilot study","volume":"25","author":"Nakano","year":"2010","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.psychres.2017.01.043_bib30","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1440-1819.2009.02015.x","article-title":"Oxidative mechanisms in schizophrenia and their relationship with illness subtype and symptom profile","volume":"63","author":"Pazvantoglu","year":"2009","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2017.01.043_bib31","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/1471-244X-11-124","article-title":"Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients","volume":"11","author":"Raffa","year":"2011","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.psychres.2017.01.043_bib32","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.pnpbp.2012.05.005","article-title":"The reduction of superoxide dismutase activity is associated with the severity of neurological soft signs in patients with schizophrenia","volume":"39","author":"Raffa","year":"2012","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2017.01.043_bib33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pnpbp.2014.10.002","article-title":"Towards stage specific treatments: effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia","volume":"57","author":"Rapado-Castro","year":"2015","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2017.01.043_bib34","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.psychres.2012.07.024","article-title":"Adaptive response in the antioxidant defence system in the course and outcome in first-episode schizophrenia patients: a 12-months follow-up study","volume":"200","author":"Ruiz-Litago","year":"2012","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2017.01.043_bib35","first-page":"1164","article-title":"Oxidative-antioxidative systems and their relation with serum S100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment. Prog. Neuropsychopharmacol","volume":"31","author":"Sarandol","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2017.01.043_bib36","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/pcn.12333","article-title":"First-episode psychosis is associated with oxidative stress: effects of short-term antipsychotic treatment","volume":"69","author":"Sarandol","year":"2015","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2017.01.043_bib37","doi-asserted-by":"crossref","first-page":"e56339","DOI":"10.1371\/journal.pone.0056339","article-title":"Serum uric acid concentrations in meat eaters, fish eaters, vegetarians and vegans: a cross-sectional analysis in the EPIC-Oxford cohort","volume":"8","author":"Schmidt","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.psychres.2017.01.043_bib38","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3945\/jn.115.218883","article-title":"Vitamin D supplementation affects the beck depression inventory,inventory, insulin resistance,resistance, and biomarkers of oxidative stress in patients with major depressive disorder:disorder a: a randomized,randomized, controlled clinical trial","volume":"146","author":"Sepehrmanesh","year":"2016","journal-title":"J. Nutr."},{"key":"10.1016\/j.psychres.2017.01.043_bib39","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.psychres.2015.07.036","article-title":"Increased oxidative stress and oxidative DNA damage in non-remission schizophrenia patients","volume":"229","author":"Sertan","year":"2015","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.psychres.2017.01.043_bib40","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1440-1819.2006.01532.x","article-title":"Total antioxidant response in patients with schizophrenia","volume":"60","author":"Ustundag","year":"2006","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.psychres.2017.01.043_bib41","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1038\/oby.2012.130","article-title":"Evaluation of oxidative stress in overweight subjects with or without metabolic syndrome","volume":"20","author":"Venturini","year":"2012","journal-title":"Obesity"},{"key":"10.1016\/j.psychres.2017.01.043_bib42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000239684","article-title":"A defect in the antioxidant defense system in schizophrenia","volume":"60","author":"Virit","year":"2009","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.psychres.2017.01.043_bib43","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4088\/JCP.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics","volume":"64","author":"Woods","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.psychres.2017.01.043_bib44","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1089\/ars.2010.3646","article-title":"Oxidative stress in schizophrenia: pathogenetic and therapeutic implications","volume":"5","author":"Yao","year":"2011","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.psychres.2017.01.043_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0920-9964(98)00030-9","article-title":"Reduced status of plasma total antioxidant capacity in schizophrenia","volume":"32","author":"Yao","year":"1998","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.psychres.2017.01.043_bib46","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.pnpbp.2013.03.003","article-title":"Oxidative stress and therapeutic implications in psychiatric disorders","volume":"46","author":"Zhang","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.psychres.2017.01.043_bib47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.schres.2012.04.009","article-title":"Plasma total antioxidant status and cognitive impairments in schizophrenia","volume":"139","author":"Zhang","year":"2012","journal-title":"Schizophr. Res."}],"container-title":["Psychiatry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178116304012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165178116304012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,26]],"date-time":"2022-06-26T04:23:14Z","timestamp":1656217394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165178116304012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":47,"alternative-id":["S0165178116304012"],"URL":"https:\/\/doi.org\/10.1016\/j.psychres.2017.01.043","relation":{},"ISSN":["0165-1781"],"issn-type":[{"value":"0165-1781","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low levels of serum total antioxidant capacity and presence at admission and absence at discharge of a day\/night change as a marker of acute paranoid schizophrenia relapse","name":"articletitle","label":"Article Title"},{"value":"Psychiatry Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.psychres.2017.01.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}